Next Generation Sequencing (NGS) Japan Market to Grow at 11.6% CAGR with Precision Oncology & Genomic Innovations

Leander, Texas and Tokyo, Japan - Jan.05.2026
As per DataM Intelligence research report "Next Generation Sequencing (NGS) Market size reached US$ 13.42 Billion in 2024 and is expected to reach US$ 35.92 Billion by 2033, growing at a CAGR of 11.6% during the forecast period 2025 to 2033." Advancements in sequencing platforms, rising applications in precision medicine, oncology, drug discovery, and declining costs are fueling demand for NGS technologies in clinical and research settings.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/next-generation-sequencing-ngs-market?sindhuri

Japan: Recent Industry Developments
✅ In May 2025, Illumina received MHLW approval in Japan for its TruSight Oncology Comprehensive genomic profiling test. The NGS-based test analyzes over 500 tumor genes, enabling broader access to precision oncology treatments.
✅ In 2025, Takara Bio advanced distribution and development of single-cell and high-throughput NGS systems. This supports biomarker discovery in oncology and aligns with Japan's growing focus on personalized medicine.
✅ In 2025, Government initiatives and investments in genomic research accelerated adoption of NGS for clinical diagnostics and companion testing in cancer care.

United States: Recent Industry Developments
✅ In February 2025, Roche launched Sequencing by Expansion (SBX) technology in the U.S. The novel Xpandomer chemistry delivers ultra-fast, high-accuracy genomic analysis for cancer and other diseases.
✅ In 2025, Illumina expanded its MiSeq i100 Series and NovaSeq platforms. These offer enhanced accessibility, throughput, and cost reductions for large-scale research and clinical applications.
✅ In January 2025, Senseera secured USD 7.1 million funding for liquid biopsy NGS technology. This advances non-invasive cancer detection and monitoring.

Next Generation Sequencing (NGS) Market: Drivers
The next generation sequencing market is driven by surging demand for precision medicine, companion diagnostics, and personalized therapies in oncology and rare diseases. Technological advancements reduce costs, improve accuracy, and enable high-throughput analysis, expanding applications in drug discovery, genetic screening, and clinical diagnostics.
Another driver is increasing prevalence of cancer and genetic disorders, regulatory approvals for NGS-based tests, and investments in genomic research. Integration of AI for data analysis, partnerships between pharma and NGS providers, and growth in academic & biopharma R&D sustain market momentum.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/next-generation-sequencing-ngs-market?sindhuri

Next Generation Sequencing (NGS) Market: Major Players
Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Qiagen, Eurofins Scientific, Revvity (PerkinElmer Inc.), Takara Bio Inc., Illumina Inc., Alithea Genomics SA, NewBiologix SA.

Segment Covered in the Next Generation Sequencing (NGS) Market:
By Product Type
The market is segmented into Reagents and Consumables, Instruments, and Others.
By Application
Drug Discovery (38.7% share), Agriculture and Animal Research, Diagnostics, Genetic Screening, and Others.
By Technology
Whole Genome Sequencing, Chip Sequencing, De Novo Sequencing, RNA Sequencing, Methyl Sequencing, and Others.
By End-User
Hospitals and Diagnostic Centers, Biotechnology and Pharmaceutical Companies, Academic & Research Institutes, and Others.

Regional Analysis
North America - Leading Share (42.3%)
North America dominates the NGS market with widespread adoption of advanced sequencing technologies, strong presence of key market players, and substantial investments in genomics research and precision medicine in the U.S. and Canada.
Europe - Significant Share (23.7%)
Europe shows strong growth driven by government-funded genomics initiatives, increasing clinical applications, and advanced research infrastructure in countries like Germany, the U.K., and France.
Asia Pacific - Strong Share (19.8%)
Asia Pacific grows steadily with rising investments in genomics research, expanding biotechnology and pharmaceutical sectors, and adoption of NGS in clinical diagnostics, particularly in China, Japan, and India.
Latin America - Gradual Growth (7.1%)
Latin America is witnessing gradual adoption of NGS technologies in research and clinical diagnostics, with countries such as Brazil, Mexico, and Argentina expanding genomic research capabilities.
Middle East & Africa - Emerging Growth (7.1%)
The Middle East and Africa are emerging markets for NGS, with growing genomics research programs, investments in healthcare infrastructure, and increasing awareness of precision medicine applications in countries like UAE, Saudi Arabia, and South Africa.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=next-generation-sequencing-ngs-market?sindhuri
(Purchase 2 or more Reports and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sindhuri
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.